Proprotein convertase subtilisin/kexin type 9 (PCSK9) affects gene expression pathways beyond cholesterol metabolism in liver cells

Journal of Cellular Physiology

Volumn 224, Issue 1, 2010, Pages 273-281

  Lan, Hong ^a   Pang, Ling ^a   Smith, Marsha M ^a   Levitan, Diane ^a   Ding, Wei ^a   Liu, Li ^a   Shan, Lixin ^a   Shah, Vidhi V ^a   Laverty, Maureen ^a   Arreaza, Gladys ^a   Zhang, Qing ^a   Murgolo, Nicholas J ^a   Hernandez, Marco ^a   Greene, Jonathan R ^a   Gustafson, Eric L ^a   Bayne, Marvin L ^a   Davis, Harry R ^a   Hedrick, Joseph A ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

KEXIN; SUBTILISIN; CHOLESTEROL; PCSK9 PROTEIN, HUMAN; RECOMBINANT PROTEIN; SERINE PROTEINASE;

ARTICLE; CELL STRAIN HEPG2; CHOLESTEROL METABOLISM; CHOLESTEROL SYNTHESIS; CONTROLLED STUDY; GENE EXPRESSION; GENOME; HUMAN; HUMAN CELL; LIVER CELL; MICROARRAY ANALYSIS; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; UPREGULATION; WILD TYPE; BIOSYNTHESIS; DNA MICROARRAY; ENZYMOLOGY; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE REGULATORY NETWORK; GENETICS; LIPID METABOLISM; LIVER TUMOR; METABOLISM; METHODOLOGY; MUTATION; PATHOLOGY; TIME;

CHOLESTEROL; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE REGULATORY NETWORKS; HEP G2 CELLS; HUMANS; LIPID METABOLISM; LIVER NEOPLASMS; MUTATION; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; RECOMBINANT PROTEINS; SERINE ENDOPEPTIDASES; TIME FACTORS;

EID: 77952493988     PISSN: 00219541     EISSN: 10974652     Source Type: Journal    
DOI: 10.1002/jcp.22130     Document Type: Article

References (19)

1. Abifadel M, Varret M, Rabes JP, Allard D, Ouguerram K, Devillers M, Cruaud C, Benjannet S, Wickham L, Erlich D, Derre A, Villeger L, Farnier M, Beucler I, Bruckert E, Chambaz J, Chanu B, Lecerf JM, Luc G, Moulin P, Weissenbach J, Prat A, Krempf M, Junien C, Seidah NG, Boileau C. 2003. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet 34:154-156. (Pubitemid 36666925)
2. Baass A, Dubuc G, Tremblay M, Delvin EE, O'Loughlin J, Levy E, Davignon J, Lambert M. 2009. Plasma PCSK9 is associated with age, sex, and multiple metabolic markers in a population-based sample of children and adolescents. Clin Chem 55:1637-1645.
3. Benjannet S, Rhainds D, Hamelin J, Nassoury N, Seidah NG. 2006. The proprotein convertase (PC) PCSK9 is inactivated by furin and/or PC5/6A: Functional consequences of natural mutations and post-translational modifications. J Biol Chem 281:30561-30572.
4. Dennis G, Jr., Sherman BT, Hosack DA, Yang J, Gao W, Lane HC, Lempicki RA. 2003. DAVID: Database for annotation, visualization, and integrated discovery. Genome Biol 4:P3.
5. Grefhorst A, McNutt MC, Lagace TA, Horton JD. 2008. Plasma PCSK9 preferentially reduces liver LDL receptors in mice. J Lipid Res 49:1303-1311.
6. Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, Scherf U, Speed TP. 2003. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 4:249-264.
7. Labonte P, Begley S, Guevin C, Asselin MC, Nassoury N, Mayer G, Prat A, Seidah NG. 2009. PCSK9 impedes hepatitis C virus infection in vitro and modulates liver CD81 expression. Hepatology 50:17-24.
8. Lagace TA, Curtis DE, Garuti R, McNutt MC, Park SW, Prather HB, Anderson NN, Ho YK, Hammer RE, Horton JD. 2006. Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice. J Clin Invest 116:2995-3005.
9. Lambert G, Ancellin N, Charlton F, Comas D, Pilot J, Keech A, Patel S, Sullivan DR, Cohn JS, Rye KA, Barter PJ. 2008. Plasma PCSK9 concentrations correlate with LDL and total cholesterol in diabetic patients and are decreased by fenofibrate treatment. Clin Chem 54:1038-1045.
10. Li J, Tumanut C, Gavigan JA, Huang WJ, Hampton EN, Tumanut R, Suen KF, Trauger JW, Spraggon G, Lesley SA, Liau G, Yowe D, Harris JL. 2007. Secreted PCSK9 promotes LDL receptor degradation independently of proteolytic activity. Biochem J 406:203-207.
11. Maxwell KN, Fisher EA, Breslow JL. 2005. Overexpression of PCSK9 accelerates the degradation of the LDLR in a post-endoplasmic reticulum compartment. Proc Natl Acad Sci USA 102:2069-2074.
12. Mayne J,Dewpura T, Raymond A, Cousins M, Chaplin A, Lahey KA, Lahaye SA, Mbikay M, Ooi TC, Chretien M. 2008. Plasma PCSK9 levels are significantly modified by statins and fibrates in humans. Lipids Health Dis 7:22.
13. McNutt MC, Lagace TA, Horton JD. 2007. Catalytic activity is not required for secreted PCSK9 to reduce low density lipoprotein receptors in HepG2 cells. J Biol Chem 282:20799-20803.
14. Moscat J, Diaz-Meco MT. 2009. p62 at the crossroads of autophagy, apoptosis, and cancer. Cell 137:1001-1004.
15. Qian YW, Schmidt RJ, Zhang Y, Chu S, Lin A, Wang H, Wang X, Beyer TP, Bensch WR, Li W, Ehsani ME, Lu D, Konrad RJ, Eacho PI, Moller DE, Karathanasis SK, Cao G. 2007. Secreted PCSK9 downregulates low density lipoprotein receptor through receptor-mediated endocytosis. J Lipid Res 48(7):1488-1498.
16. Ranheim T, Mattingsdal M, Lindvall JM, Holla OL, Berge KE, Kulseth MA, Leren TP. 2008. Genome-wide expression analysis of cells expressing gain of function mutant D374YPCSK9. J Cell Physiol 217:459-467.
17. Seibenhener ML, Geetha T, Wooten MW. 2007. Sequestosome 1/p62-more than just a scaffold. FEBS Lett 581:175-179.
18. Seidah NG. 2009. PCSK9 as a therapeutic target of dyslipidemia. Expert Opin Ther Targets 13:19-28.
19. Zelcer N, Hong C, Boyadjian R, Tontonoz P. 2009. LXR regulates cholesterol uptake through Idol-dependent ubiquitination of the LDL receptor. Science 325:100-104.